Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 23 · below the Ichimoku cloud · RSI 36 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $401.1K | 0.00% | 16.20K | −16% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PRPO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 14, 2026 | Cohen David SethDirector | Stock Award(Grant) at price 25.24 per share. | 520 | $13.13K |
| Jul 14, 2026 | Cossman Jeffrey M.D.Director | Stock Award(Grant) at price 25.24 per share. | 416 | $10.50K |
| Jul 14, 2026 | Valauri Christina RizopoulosDirector | Stock Award(Grant) at price 25.24 per share. | 108 | $2.73K |
| May 20, 2026 | Sandberg Richard ADirector | Sale at price 25.02 per share. | 900 | $22.52K |
| May 19, 2026 | Sandberg Richard ADirector | Sale at price 24.42 - 25.00 per share. | 3.1K | $77.78K |
| Apr 14, 2026 | Cohen David SethDirector | Stock Award(Grant) at price 29.49 per share. | 445 | $13.12K |
| Apr 14, 2026 | Cossman Jeffrey M.D.Director | Stock Award(Grant) at price 29.49 per share. | 365 | $10.76K |
| Apr 14, 2026 | Valauri Christina RizopoulosDirector | Stock Award(Grant) at price 29.49 per share. | 93 | $2.74K |
| Mar 31, 2026 | Sabet Ahmed ZakiChief Operating Officer | Purchase at price 27.93 per share. | 19 | $531 |
| Jan 14, 2026 | Cohen David SethDirector | Stock Award(Grant) at price 24.00 per share. | 546 | $13.10K |
| Jan 14, 2026 | Cossman Jeffrey M.D.Director | Stock Award(Grant) at price 24.00 per share. | 437 | $10.49K |
| Jan 14, 2026 | Valauri Christina RizopoulosDirector | Stock Award(Grant) at price 24.00 per share. | 406 | $9.74K |
| Jan 14, 2026 | Laporte Kathleen DDirector | Stock Award(Grant) at price 24.00 per share. | 520 | $12.48K |
| Jan 1, 2026 | Sabet Ahmed ZakiChief Operating Officer | Purchase at price 23.40 per share. | 20 | $468 |
| Jan 1, 2026 | Sabet Ahmed ZakiChief Operating Officer | Purchase at price 23.40 per share. | 20 | $468 |
| Oct 14, 2025 | Cohen David SethDirector | Stock Award(Grant) at price 17.58 per share. | 746 | $13.12K |
| Oct 14, 2025 | Cohen David SethDirector | Stock Award(Grant) at price 17.58 per share. | 746 | $13.12K |
| Oct 14, 2025 | Cossman Jeffrey M.D.Director | Stock Award(Grant) at price 17.58 per share. | 597 | $10.49K |
| Oct 14, 2025 | Cossman Jeffrey M.D.Director | Stock Award(Grant) at price 17.58 per share. | 597 | $10.49K |
| Oct 14, 2025 | Laporte Kathleen DDirector | Stock Award(Grant) at price 17.58 per share. | 711 | $12.50K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.8 | -1.9 | 3.8 | 23.6 | -26.2 | 8.6 | -12.6 | 27.9 | -14.5 | -4.6 | −1.7% | ||
| 2025 | 24.0 | 5.9 | -13.9 | -3.0 | 55.2 | 16.9 | 29.2 | 8.8 | 14.6 | 15.2 | 18.7 | -5.5 | +314.8% |
| 2024 | -1.8 | 4.3 | 0.6 | -14.2 | 0.2 | -9.9 | -2.5 | 29.6 | 2.1 | -4.3 | -7.3 | -6.8 | −14.8% |
| 2023 | 65.2 | -8.7 | -20.1 | -8.1 | -4.9 | -32.8 | -15.1 | -0.3 | -15.0 | 40.1 | -13.2 | -4.8 | −41.0% |
| 2022 | -18.4 | 18.6 | -11.8 | -20.7 | 6.5 | -7.0 | 15.1 | -3.3 | -31.9 | 0.7 | -5.3 | -28.2 | −65.1% |
| 2021 | 37.2 | -14.1 | -5.3 | -21.2 | 81.9 | 9.7 | -14.3 | 8.4 | -16.3 | -16.3 | -17.8 | -18.6 | −23.7% |
| 2020 | -8.5 | -18.4 | -54.2 | 5.3 | 13.7 | 69.5 | 121.1 | -30.6 | 12.4 | -20.8 | 16.0 | -8.0 | +1.0% |
| 2019 | 22.1 | -16.0 | -20.9 | 222.7 | -9.9 | -38.0 | -13.6 | -13.0 | 2.8 | -9.2 | -10.8 | -3.1 | −11.3% |
| 2018 | -5.0 | -43.9 | -16.1 | -21.2 | 7.6 | -19.1 | 7.6 | 1.0 | -1.3 | -31.6 | -14.4 | -33.3 | −87.2% |
| 2017 | -8.9 | -72.2 | -5.3 | -9.7 | -33.3 | -7.7 | −86.7% |
No analyst coverage for this instrument.
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.